Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Keryx Biopharma (KERX) Misses Q1 EPS by 13c
April 28, 2016 8:53 AM EDTKeryx Biopharma (NASDAQ: KERX) reported Q1 EPS of ($0.39), $0.13 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $6.63 million.
Total operating expenses (excluding cost of goods sold and license expenses) for the first quarter ended March 31, 2016... More
